In line with tumor mRNA analysis, SMARCA4 IHC-negative NSCLC tumors (n = 11) expressed lower levels of cyclin D1 compared to SMARCA4 IHC-positive NSCLCs (n = 82) although not statistically significant (p = 0.105; Fig. 3h, i). This evidence concerns the gene CCND1 and neoplasm.